PMID- 37088045
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230601
IS  - 1879-1379 (Electronic)
IS  - 0022-3956 (Linking)
VI  - 162
DP  - 2023 Jun
TI  - Assessment of cognitive impairment and depressive signs in patients with type 2 
      diabetes treated with metformin from Southeast Mexico: A cross-sectional study.
PG  - 65-70
LID - S0022-3956(23)00171-1 [pii]
LID - 10.1016/j.jpsychires.2023.04.007 [doi]
AB  - Multiple factors associate diabetes with cognitive impairment and depression. 
      Antidiabetic drugs have reported antidepressant and pro-cognitive effects in 
      diabetic and non-diabetic subjects. Antidepressant and pro-cognitive effects of 
      metformin are reported in various studies; however, these effects are not 
      consistent among researches. We designed a cross-sectional study. We recruited 
      patients with T2D diagnosis from the Diabetes Clinic of the Regional Hospital of 
      High Specialty "Dr. Gustavo A. Rovirosa Perez" from January 2019 to May 2022. We 
      included 431 subjects with T2D, 374 patients with metformin treatment and 57 
      subjects without metformin. These patients were on intensive therapies and had 
      not a previous diagnosis of cognitive impairment or depression. We applied 
      Mini-Mental State Examination (MMSE) to evaluate cognitive impairment, and 
      Hamilton Depression Rating Scale (HAM-D) to assess depressive signs. Our sample 
      had a mean age of 53.77 +/- 13.43 years. Metformin users were 374 individuals, and 
      57 subjects didn't use metformin. MMSE found cognitive impairment in 8.3% 
      (n = 31) of metformin users, and 14.8% (n = 8) of patients without metformin. 
      HAM-D scale showed that 39.5% (n = 147) of patients with metformin had depression 
      signs, subjects without metformin and depressive signs were 44.6% (n = 25). We 
      found no differences between groups for cognitive impairment and depression 
      grades. We did not find associations between metformin treatment, cognitive 
      impairment measures and depression sign measures. However, chronic metformin 
      treatment, insulin use, glycemic control and age could influence our results.
CI  - Copyright (c) 2023. Published by Elsevier Ltd.
FAU - Nolasco-Rosales, German Alberto
AU  - Nolasco-Rosales GA
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica de Ciencias de la 
      Salud, Villahermosa, Tabasco, Mexico.
FAU - Villar-Juarez, Guillermo Efren
AU  - Villar-Juarez GE
AD  - Escuela de Medicina. Universidad Anahuac Queretaro. Queretaro, Queretaro, Mexico.
FAU - Perez-Osorio, Daniel Arturo
AU  - Perez-Osorio DA
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica de Ciencias de la 
      Salud, Villahermosa, Tabasco, Mexico.
FAU - Cruz-Castillo, Juan Daniel
AU  - Cruz-Castillo JD
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica de Ciencias de la 
      Salud, Villahermosa, Tabasco, Mexico.
FAU - Molina-Guzman, Gabriel
AU  - Molina-Guzman G
AD  - Instituto Mexicano del Seguro Social, Hospital General de Zona 46, Villahermosa, 
      Tabasco, Mexico; Instituto de Seguridad y Servicios Sociales de los Trabajadores 
      del Estado, Hospital General Dr. Daniel Gurria Urgell, Villahermosa, Tabasco, 
      Mexico.
FAU - Gonzalez-Castro, Thelma Beatriz
AU  - Gonzalez-Castro TB
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica Multidisciplinaria de 
      Jalpa de Mendez, Jalpa de Mendez, Tabasco, Mexico.
FAU - Tovilla-Zarate, Carlos Alfonso
AU  - Tovilla-Zarate CA
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica Multidisciplinaria de 
      Comalcalco, Comalcalco, Tabasco, Mexico.
FAU - Rodriguez-Sanchez, Ester
AU  - Rodriguez-Sanchez E
AD  - Hospital Regional de Alta Especialidad "Gustavo A. Rovirosa Perez", Villahermosa, 
      Tabasco, Mexico.
FAU - Genis-Mendoza, Alma Delia
AU  - Genis-Mendoza AD
AD  - Departamento de Genetica Psiquiatrica, Instituto Nacional de Medicina Genomica, 
      Ciudad de Mexico, Mexico.
FAU - Hernandez-Palacios, Filiberto
AU  - Hernandez-Palacios F
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica de Ciencias de la 
      Salud, Villahermosa, Tabasco, Mexico.
FAU - Juarez-Rojop, Isela Esther
AU  - Juarez-Rojop IE
AD  - Universidad Juarez Autonoma de Tabasco, Division Academica de Ciencias de la 
      Salud, Villahermosa, Tabasco, Mexico. Electronic address: 
      iselajuarezrojop@hotmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230410
PL  - England
TA  - J Psychiatr Res
JT  - Journal of psychiatric research
JID - 0376331
RN  - 9100L32L2N (Metformin)
RN  - 0 (Antidepressive Agents)
SB  - IM
MH  - Humans
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Metformin/therapeutic use
MH  - Cross-Sectional Studies
MH  - Mexico/epidemiology
MH  - *Cognitive Dysfunction/diagnosis/epidemiology/etiology
MH  - Antidepressive Agents/therapeutic use
OTO - NOTNLM
OT  - Cognitive impairment
OT  - Depression
OT  - Metformin
OT  - Type 2 diabetes mellitus
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/04/24 00:41
MHDA- 2023/05/29 06:42
CRDT- 2023/04/23 18:14
PHST- 2022/11/04 00:00 [received]
PHST- 2023/03/21 00:00 [revised]
PHST- 2023/04/05 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/04/24 00:41 [pubmed]
PHST- 2023/04/23 18:14 [entrez]
AID - S0022-3956(23)00171-1 [pii]
AID - 10.1016/j.jpsychires.2023.04.007 [doi]
PST - ppublish
SO  - J Psychiatr Res. 2023 Jun;162:65-70. doi: 10.1016/j.jpsychires.2023.04.007. Epub 
      2023 Apr 10.